Lupin launches authorized generic version of Alinia
News

Lupin launches authorized generic version of Alinia

Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.

  • By IPP Bureau | March 13, 2021

Global pharma major Lupin has announced the launch of the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories.

 

Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.

 

Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S. (IQVIA MAT January 2021).

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International